Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
Ronan J. Kelly(Inserm), Jaffer A. Ajani(The University of Texas MD Anderson Cancer Center), Jarosław Kużdżał(Jagiellonian University), Thomas Zander(Inserm), Eric Van Cutsem(Inserm), Guillaume Piessen(Inserm), Guillermo Méndez(Inserm), Josephine Feliciano(Johns Hopkins University), Satoru Motoyama(Inserm), Astrid Lièvre(Inserm), Hope E. Uronis(Inserm), Elena Elimova(Inserm), Cecile Grootscholten(Inserm), Karen Geboes(Inserm), Syed Zafar(Inserm), Stephanie Snow(Inserm), Andrew H. Ko(Inserm), Kynan Feeney(Inserm), Michael Schenker(Inserm), Piotr Kocoń(Jagiellonian University), Jenny Zhang(Inserm), Lili Zhu(Inserm), Ming Lei(Inserm), Prianka Singh(Inserm), Kaoru Kondo(Inserm), James M. Cleary(Inserm), Markus Moehler(Inserm)
Cited by 1,737Open Access
Abstract
Among patients with resected esophageal or gastroesophageal junction cancer who had received neoadjuvant chemoradiotherapy, disease-free survival was significantly longer among those who received nivolumab adjuvant therapy than among those who received placebo. (Funded by Bristol Myers Squibb and Ono Pharmaceutical; CheckMate 577 ClinicalTrials.gov number, NCT02743494.).
Related Papers
No related papers found
Powered by citation graph analysis